everdrin forte 250mg/250mg/65mg tableta
laboratorios quilla pharma peru s.a.c. - droguerÍa - paracetamol; acido acetilsalicilico; cafeina; - tableta - por tableta - - Ácido acetilsalicílico, combinaciones excl. psicolépticos
nomigrat 250 mg + 250 mg + 65 mg tableta recubierta
oqcorp sociedad anonima cerrada - oqcorp s.a.c. - droguerÍa - paracetamol; acido acetilsalicilico; cafeina; - tableta recubierta - por tableta - - paracetamol
tonopan migraña 250mg+250mg+65mg tableta recubierta
ansolat sociedad anonima cerrada - ansolat - droguerÍa - paracetamol; acido acetilsalicilico; cafeina; - tableta recubierta - por tableta - - otros agentes antiinflamatorios/antirreumáticos en combinación con otras drogas
migrapac . tableta
sherfarma s.a.c. - paracetamol; acido acetilsalicilico; cafeina; - tableta - por tableta - otros agentes antiinflamatorios/antirreumáticos en combinación con otras drogas
dolcaf 250mg+250mg+65mg tableta recubierta
ansolat sociedad anonima cerrada - ansolat - droguerÍa - paracetamol; acido acetilsalicilico; cafeina; - tableta recubierta - por tableta - - paracetamol, combinaciones excl. psicolÉpticos
cefadol 250mg+250mg+65mg tableta
inretail pharma s.a. - paracetamol; acido acetilsalicilico; cafeina; - tableta - por tableta - paracetamol, combinaciones excl. psicolÉpticos
paramidol migraña . tableta
laboratorios farmaceuticos markos s.a. - paracetamol; cafeina; acido acetilsalicilico; - tableta - por tableta - paracetamol, combinaciones excl. psicolÉpticos
sevedol migraña 250 mg + 250 mg + 65 mg tableta
farmindustria s.a. - droguerÍa - cafeina; paracetamol; acido acetilsalicilico; - tableta - por tableta - - cafeína
clopidogrel acino
acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - agentes antitrombóticos - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - besilato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agentes antitrombóticos - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). elevación del segmento st infarto agudo de miocardio, en combinación con aas en los pacientes tratados médicamente elegibles para la terapia trombolítica. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. para más información, por favor refiérase a la sección 5.